Litcius/Paper detail

O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial

Bradley J. Monk, Takafumi Toita, Xiaohua Wu, Juan Carlos Vázquez Limón, Qi Zhou, R. Tarnawski, Masaki Mandai, Ronnie Shapira‐Frommer, Umesh Mahantshetty, Maria Del Pilar Estevez-Diz, Francisco Ramirez Godinez, Szilvia Varga, M.H. Leiva Gálvez, Jung‐Yun Lee, Yulia Kreynina, Kathryn Howells, Sophie Wildsmith, Hannah Dry, Ana T. Nunes, Jyoti Mayadev

2022International Journal of Gynecological Cancer15 citationsDOIOpen Access PDF

Topics & Concepts

DurvalumabMedicinePlaceboClinical endpointChemoradiotherapyInternal medicineAdverse effectCervical cancerUrologyOncologySurgeryRandomized controlled trialCancerNivolumabPathologyImmunotherapyAlternative medicineEndometrial and Cervical Cancer TreatmentsReproductive System and PregnancyCancer Immunotherapy and Biomarkers
O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial | Litcius